The prostate-specific membrane antigen positron emission tomography (PSMA PET) agent 64Cu-SAR-bisPSMA has now been granted a second quick observe designation by the Meals and Drug Administration (FDA) for prostate most cancers (PCa) imaging.
The PET agent’s newest FDA quick observe designation, for biochemical PCa recurrence in sufferers who’ve had definitive remedy, comes 5 months after the preliminary quick observe designation for suspected metastasis in sufferers who’re candidates for definitive PCa therapy, in keeping with Readability Prescribed drugs, the developer of 64Cu-SAR-bisPSMA.
Right here one can see a comparability of the PET brokers 64Cu-SAR-bisPSMA and 68Ga PSMA-11 PET/CT. The FDA has granted two quick observe designations for 64Cu-SAR-bisPSMA with the newest one being for biochemical prostate most cancers recurrence in sufferers who’ve had definitive remedy. (Photos courtesy of the Society of Nuclear Drugs and Molecular Imaging (SNMMI).)
“Receiving the second (quick observe designation) for 64Cu-SAR-bisPSMA and nicely inside the 60-day interval following our utility submission, reserved by the U.S. FDA for assessment, is one more important milestone in our bisPSMA program,” famous Alan Taylor, Ph.D., the manager chairperson of Readability Prescribed drugs. “This highlights the excessive unmet want for novel diagnostics in prostate most cancers and the prime quality of information we offered to the FDA.”
Emphasizing the elevated uptake of 64Cu-SAR-bisPSMA in PCa lesions, Readability Prescribed drugs famous that latest analysis has demonstrated the flexibility of 64Cu-SAR-bisPSMA to diagnose recurrent lesions within the 2 mm vary months earlier than detection by different PSMA PET brokers.
